BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 31813897)

  • 1. Open-Label Two-Dose Pilot Study of Landiolol for the Treatment of Atrial Fibrillation/Atrial Flutter in Caucasian Patients.
    Stix G; Wolzt M; Domanovits H; Kadlecová P; Husch B; Trebs M; Hodisch J; Unger M; Krumpl G
    Circ J; 2019 Dec; 84(1):33-42. PubMed ID: 31813897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urgent management of rapid heart rate in patients with atrial fibrillation/flutter and left ventricular dysfunction: comparison of the ultra-short-acting β1-selective blocker landiolol with digoxin (J-Land Study).
    Nagai R; Kinugawa K; Inoue H; Atarashi H; Seino Y; Yamashita T; Shimizu W; Aiba T; Kitakaze M; Sakamoto A; Ikeda T; Imai Y; Daimon T; Fujino K; Nagano T; Okamura T; Hori M;
    Circ J; 2013; 77(4):908-16. PubMed ID: 23502991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impacts of patient characteristics on the effectiveness of landiolol in AF/AFL patients complicated with LV dysfunction: Subgroup analysis of the J-Land study.
    Kinugawa K; Nagai R; Inoue H; Atarashi H; Seino Y; Yamashita T; Shimizu W; Aiba T; Kitakaze M; Sakamoto A; Ikeda T; Imai Y; Daimon T; Fujino K; Nagano T; Okamura T; Hori M;
    Adv Ther; 2014 Apr; 31(4):426-39. PubMed ID: 24643403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design of a prospective observational survey on landiolol in atrial fibrillation/atrial flutter patients with chronic heart failure - AF-CHF landiolol survey.
    Yamashita T; Saitoh T; Matsushita M
    J Cardiol; 2015 Jul; 66(1):69-72. PubMed ID: 25454208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective observational survey on landiolol in atrial fibrillation/atrial flutter patients with chronic heart failure - AF-CHF landiolol survey.
    Yamashita T; Nakasu Y; Mizutani H; Sumitani K
    J Cardiol; 2019 Nov; 74(5):418-425. PubMed ID: 31255463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of landiolol hydrochloride, an ultra-short-acting beta 1-selective blocker, on supraventricular tachycardia, atrial fibrillation and flutter after pulmonary resection.
    Nakano T; Shimizu K; Kawashima O; Kamiyoshihara M; Nagashima T; Ibe T; Takeyoshi I
    J Clin Pharm Ther; 2012 Aug; 37(4):431-5. PubMed ID: 22059486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential Effectiveness of Landiolol Between Atrial Fibrillation and Atrial Flutter/Atrial Tachycardia Patients With Left Ventricular Dysfunction.
    Oka E; Iwasaki YK; Maru E; Fujimoto Y; Ito-Hagiwara K; Hayashi H; Yamamoto T; Yodogawa K; Hayashi M; Shimizu W
    Circ J; 2019 Mar; 83(4):793-800. PubMed ID: 30814430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alteration of fatal 1:1 conducted atrial flutter to less conducted ratio by landiolol infusion.
    Takata J; Haruyama N; Arashi T; Mae T
    J Anesth; 2016 Aug; 30(4):716-9. PubMed ID: 27085543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of landiolol, an ultra-short-acting β1-selective antagonist, for treatment of sepsis-related tachyarrhythmia (J-Land 3S): a multicentre, open-label, randomised controlled trial.
    Kakihana Y; Nishida O; Taniguchi T; Okajima M; Morimatsu H; Ogura H; Yamada Y; Nagano T; Morishima E; Matsuda N;
    Lancet Respir Med; 2020 Sep; 8(9):863-872. PubMed ID: 32243865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effectiveness and safety of landiolol hydrochloride, an ultra-short-acting β1-blocker, in postoperative patients with supraventricular tachyarrhythmias: a multicenter, randomized, double-blind, placebo-controlled study.
    Taenaka N; Kikawa S
    Am J Cardiovasc Drugs; 2013 Oct; 13(5):353-64. PubMed ID: 23818039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study design for control of HEART rate in inFant and child tachyarrhythmia with heart failure Using Landiolol (HEARTFUL): A prospective, multicenter, uncontrolled clinical trial.
    Sumitomo N; Horigome H; Miura M; Ono H; Ueda H; Takigiku K; Yoshimoto J; Ohashi N; Suzuki T; Sagawa K; Ushinohama H; Takahashi K; Miyazaki A; Sakaguchi H; Iwamoto M; Takamuro M; Tokunaga C; Nagano T;
    J Cardiol; 2017 Sep; 70(3):232-237. PubMed ID: 28073682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A low-dose β1-blocker effectively and safely slows the heart rate in patients with acute decompensated heart failure and rapid atrial fibrillation.
    Kobayashi S; Murakami W; Myoren T; Tateishi H; Okuda S; Doi M; Nao T; Wada Y; Matsuzaki M; Yano M
    Cardiology; 2014; 127(2):105-13. PubMed ID: 24296610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Landiolol, an ultra-short-acting β₁-blocker, more effectively terminates atrial fibrillation than diltiazem after open heart surgery: prospective, multicenter, randomized, open-label study (JL-KNIGHT study).
    Sakamoto A; Kitakaze M; Takamoto S; Namiki A; Kasanuki H; Hosoda S;
    Circ J; 2012; 76(5):1097-101. PubMed ID: 22361918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postoperative administration of landiolol hydrochloride for patients with supraventricular arrhythmia: the efficacy of sustained intravenous infusion at a low dose.
    Wariishi S; Yamashita K; Nishimori H; Fukutomi T; Yamamoto M; Radhakrishnan G; Sasaguri S
    Interact Cardiovasc Thorac Surg; 2009 Nov; 9(5):811-3. PubMed ID: 19666952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel use of the ultra-short-acting intravenous β1-selective blocker landiolol for supraventricular tachyarrhythmias in patients with congestive heart failure.
    Adachi T; Sato A; Baba M; Hiraya D; Hasegawa T; Kuroki K; Hoshi T; Aonuma K
    Heart Vessels; 2014 Jul; 29(4):464-9. PubMed ID: 23801459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and pharmacodynamics of two different landiolol formulations in a healthy Caucasian group.
    Krumpl G; Ulc I; Trebs M; Kadlecová P; Hodisch J
    Eur J Pharm Sci; 2016 Sep; 92():64-73. PubMed ID: 27373605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bolus application of landiolol and esmolol: comparison of the pharmacokinetic and pharmacodynamic profiles in a healthy Caucasian group.
    Krumpl G; Ulc I; Trebs M; Kadlecová P; Hodisch J
    Eur J Clin Pharmacol; 2017 Apr; 73(4):417-428. PubMed ID: 28091703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of low-dose landiolol, an ultrashort-acting beta-blocker, on postoperative atrial fibrillation after CABG surgery.
    Fujiwara H; Sakurai M; Namai A; Kawamura T
    Gen Thorac Cardiovasc Surg; 2009 Mar; 57(3):132-7. PubMed ID: 19280308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of landiolol hydrochloride after off-pump coronary artery bypass.
    Maisawa K; Yamazaki K; Ishitoya H; Shimamura Y
    Asian Cardiovasc Thorac Ann; 2013 Apr; 21(2):170-5. PubMed ID: 24532615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of landiolol hydrochloride for atrial fibrillation after open heart surgery.
    Nishi H; Sakaguchi T; Miyagawa S; Yoshikawa Y; Fukushima S; Saito S; Ueno T; Kuratani T; Sawa Y
    Heart Vessels; 2013 Jul; 28(4):490-6. PubMed ID: 22661097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.